Annotation Detail
Information
- Associated Genes
- ERBB2
- Associated Variants
-
ERBB2 OVEREXPRESSION
ERBB2 OVEREXPRESSION - Associated Disease
- pancreatic cancer
- Source Database
- CIViC Evidence
- Description
- Patients with metastatic pancreatic cancer with IHC 2+/3+ HER2 received gemcitabine and Trastuzumab combination. Screening logs demonstrated the rate of HER2 overexpression was 16%. Thirty-four patients were enrolled. Thirty patients (88%) had pancreatic cancers with 2+ overexpression and 4 patients (12%) had 3+ overexpression. Confirmed partial responses were observed in 2 of 32 patients (6%). The median survival for all 34 patients was 7 months.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5956
- Gene URL
- https://civic.genome.wustl.edu/links/genes/20
- Variant URL
- https://civic.genome.wustl.edu/links/variants/875
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Pancreatic Cancer
- Evidence Direction
- Does Not Support
- Drug
- Trastuzumab,Gemcitabine
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 15581051
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Gemcitabine | Sensitivity | false |
| Trastuzumab | Sensitivity | false |